Alterations in Corticostriatal Synaptic Function in Huntington's and Parkinson's Diseases

Handbook of Behavioral Neuroscience

Volumn 20, Issue C, 2010, Pages 607-623

  Cepeda, Carlos ^a   Bamford, Nigel S ^b   André, Véronique M ^b   Levine, Michael S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865621048     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-374767-9.00035-4     Document Type: Chapter

References (159)

1. Albin, RL, Young, AB, Penney, JB, The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989), 366-375.
2. Alexander, GE, Crutcher, MD, Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13 (1990), 266-271.
3. Ariano, MA, Aronin, N, Difiglia, M, Tagle, DA, Sibley, DR, Leavitt, BR, Hayden, MR, Levine, MS, Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res 68 (2002), 716-729.
4. Ariano, MA, Cepeda, C, Calvert, CR, et al. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 93 (2005), 2565-2574.
5. Ballion, B, Mallet, N, Bezard, E, Lanciego, JL, Gonon, F, Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism. Eur J Neurosci 27 (2008), 2313-2321.
6. Bamford, NS, Robinson, S, Palmiter, RD, Joyce, JA, Moore, C, Meshul, CK, Dopamine modulates release from corticostriatal terminals. J Neurosci 24 (2004), 9541-9552.
7. Bamford, NS, Zhang, H, Schmitz, Y, et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42 (2004), 653-663.
8. Bates, GP, Murphy, KP, Mouse models of Huntington's disease. Bates, GP, Harper, AL, Jones, AL, (eds.) Huntington's Disease, 2002, Oxford University Press, Oxford, UK, 387-426.
9. Berretta, S, Parthasarathy, HB, Graybiel, AM, Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J Neurosci 17 (1997), 4752-4763.
10. Bibb, JA, Yan, Z, Svenningsson, P, et al. Severe deficiences in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97 (2000), 6809-6814.
11. Blandini, F, Armentero, MT, Martignoni, E, The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:Suppl 2 (2008), S124–S129.
12. Brown, TB, Bogush, AI, Ehrlich, ME, Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet 17 (2008), 3095-3104.
13. Calabresi, P, Mercuri, NB, Sancesario, G, Bernardi, G, Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:Pt 2 (1993), 433-452.
14. Carter, RJ, Lione, LA, Humby, T, Mangiarini, L, Mahal, A, Bates, GP, Dunnett, SB, Morton, AJ, Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19 (1999), 3248-3257.
15. Cepeda, C, Levine, MS, Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE, 2006, 2006, pe20.
16. Cepeda, C, Buchwald, NA, Levine, MS, Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90 (1993), 9576-9580.
17. Cepeda, C, Wu, N, Andre, VM, Cummings, DM, Levine, MS, The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81 (2007), 253-271.
18. Cepeda, C, Walsh, JP, Hull, CD, Howard, SG, Buchwald, NA, Levine, MS, Dye-coupling in the neostriatum of the rat: I. Modulation by dopamine-depleting lesions. Synapse 4 (1989), 229-237.
19. Cepeda, C, Andre, VM, Yamazaki, I, Wu, N, Kleiman-Weiner, M, Levine, MS, Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci 27 (2008), 671-682.
20. Cepeda, C, Hurst, RS, Calvert, CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23 (2003), 961-969.
21. Cepeda, C, Starling, AJ, Wu, N, Nguyen, OK, Uzgil, B, Soda, T, Andre, VM, Ariano, MA, Levine, MS, Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78 (2004), 855-867.
22. Cepeda, C, Hurst, RS, Altemus, KL, et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85 (2001), 659-670.
23. Cha, JH, Kosinski, CM, Kerner, JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95 (1998), 6480-6485.
24. Chartoff, EH, Marck, BT, Matsumoto, AM, Dorsa, DM, Palmiter, RD, Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci USA 98 (2001), 10451-10456.
25. Chen, L, Ding, Y, Cagniard, B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28 (2008), 425-433.
26. Chen, L, Cagniard, B, Mathews, T, et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280 (2005), 21418-21426.
27. Chesselet, MF, Fleming, S, Mortazavi, F, Meurers, B, Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism Relat Disord 14:Suppl 2 (2008), S84–S87.
28. Cummings, DM, Milnerwood, AJ, Dallerac, GM, et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 15 (2006), 2856-2868.
29. Cummings, DM, André, VM, Uzgil, BO, Gee, SM, Fisher, YE, Cepeda, C, Levine, MS, Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29 (2009), 10371-10386.
30. Cyr, M, Beaulieu, JM, Laakso, A, et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci USA 100 (2003), 11035-11040.
31. Dani, JA, Zhou, FM, Selective dopamine filter of glutamate striatal afferents. Neuron 42 (2004), 522-524.
32. Davies, SW, Turmaine, M, Cozens, BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997), 537-548.
33. Day, M, Wang, Z, Ding, J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9 (2006), 251-259.
34. DiFiglia, M, Sapp, E, Chase, K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14 (1995), 1075-1081.
35. Ding, J, Peterson, JD, Surmeier, DJ, Corticostriatal and thalamostriatal synapses have distinctive properties. J Neurosci 28 (2008), 6483-6492.
36. Fan, MM, Raymond, LA, N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81 (2007), 272-293.
37. Fischer, E, Heller, B, Pharmacology of the mechanism of certain effects of reserpine in the rat. Nature 216 (1967), 1221-1222.
38. Fleming, SM, Fernagut, PO, Chesselet, MF, Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2 (2005), 495-503.
39. Fleming, SM, Tetreault, NA, Mulligan, CK, Hutson, CB, Masliah, E, Chesselet, MF, Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28 (2008), 247-256.
40. Fleming, SM, Salcedo, J, Hutson, CB, Rockenstein, E, Masliah, E, Levine, MS, Chesselet, MF, Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 142 (2006), 1245-1253.
41. Flores-Hernandez, J, Galarraga, E, Bargas, J, Dopamine selects glutamatergic inputs to neostriatal neurons. Synapse 25 (1997), 185-195.
42. Florio, T, Di Loreto, S, Cerrito, F, Scarnati, E, Influence of prelimbic and sensorimotor cortices on striatal neurons in the rat: electrophysiological evidence for converging inputs and the effects of 6-OHDA-induced degeneration of the substantia nigra. Brain Res 619 (1993), 180-188.
43. Fusco, FR, Martorana, A, De March, Z, Viscomi, MT, Sancesario, G, Bernardi, G, Huntingtin distribution among striatal output neurons of normal rat brain. Neurosci Lett 339 (2003), 53-56.
44. Fusco, FR, Chen, Q, Lamoreaux, WJ, et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19 (1999), 1189-1202.
45. Galarraga, E, Bargas, J, Martinez-Fong, D, Aceves, J, Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons. Neurosci Lett 81 (1987), 351-355.
46. Gerfen, CR, Engber, TM, Mahan, LC, Susel, Z, Chase, TN, Monsma, FJ Jr., Sibley, DR, D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990), 1429-1432.
47. Gertler, TS, Chan, CS, Surmeier, DJ, Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 28 (2008), 10814-10824.
48. Gil, JM, Rego, AC, Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27 (2008), 2803-2820.
49. Goldberg, MS, Pisani, A, Haburcak, M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005), 489-496.
50. Goldberg, MS, Fleming, SM, Palacino, JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278 (2003), 43628-43635.
51. Graham, RK, Pouladi, MA, Joshi, P, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29 (2009), 2193-2204.
52. Gray M, Gu X, Shiraski D, Cepeda C, Yamazaki I, Levine MS, Yang X (2008a) Cortical control of striatal pathogenesis in the Cre/LoxP conditional BAC transgenic mouse model of Huntington's Disease (BACHD) Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience Program No. 114.6.
53. Gray, M, Shirasaki, DI, Cepeda, C, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28 (2008), 6182-6195.
54. Graybiel, AM, Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13 (1990), 244-254.
55. Greenamyre, JT, Betarbet, R, Sherer, TB, The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9:Suppl 2 (2003), S59–S64.
56. Gu, X, Andre, VM, Cepeda, C, Li, SH, Li, XJ, Levine, MS, Yang, XW, Pathological cell–cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegen, 2, 2007, 8.
57. Gu, X, Li, C, Wei, W, et al. Pathological cell–cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46 (2005), 433-444.
58. Gubellini, P, Picconi, B, Bari, M, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22 (2002), 6900-6907.
59. Haber, SN, Nauta, WJ, Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. Neuroscience 9 (1983), 245-260.
60. Harper, PS, New genes for old diseases: the molecular basis of myotonic dystrophy and Huntington's disease. The Lumleian Lecture 1995. J R Coll Physicians Lond 30 (1996), 221-231.
61. Hashimoto, M, Rockenstein, E, Masliah, E, Transgenic models of alpha-synuclein pathology: past, present, and future. Ann NY Acad Sci 991 (2003), 171-188.
62. Hernandez-Echeagaray, E, Starling, AJ, Cepeda, C, Levine, MS, Modulation of AMPA currents by D2 dopamine receptors in striatal medium-sized spiny neurons: are dendrites necessary?. Eur J Neurosci 19 (2004), 2455-2463.
63. Hickey, MA, Reynolds, GP, Morton, AJ, The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem 81 (2002), 46-59.
64. Hickey, MA, Kosmalska, A, Enayati, J, Cohen, R, Zeitlin, S, Levine, MS, Chesselet, MF, Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157 (2008), 280-295.
65. Hodgson, JG, Agopyan, N, Gutekunst, CA, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999), 181-192.
66. Huang, CC, Lo, SW, Hsu, KS, Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532 (2001), 731-748.
67. Hull, CD, Levine, MS, Buchwald, NA, Heller, A, Browning, RA, The spontaneous firing pattern of forebrain neurons. I. The effects of dopamine and non-dopamine depleting lesions on caudate unit firing patterns. Brain Res 73 (1974), 241-262.
68. Ingham, CA, Hood, SH, van Maldegem, B, Weenink, A, Arbuthnott, GW, Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 93 (1993), 17-27.
69. Itier, JM, Ibanez, P, Mena, MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12 (2003), 2277-2291.
70. Jankovic, J, Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79 (2008), 368-376.
71. Johnson, MA, Rajan, V, Miller, CE, Wightman, RM, Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem 97 (2006), 737-746.
72. Joshi, PR, Wu, NP, Andre, VM, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29 (2009), 2414-2427.
73. Kawaguchi, Y, Wilson, CJ, Emson, PC, Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 10 (1990), 3421-3438.
74. Kemp, JM, Powell, TP, The cortico-striate projection in the monkey. Brain 93 (1970), 525-546.
75. Kim, DS, Szczypka, MS, Palmiter, RD, Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20 (2000), 4405-4413.
76. Kita, H, Kitai, ST, Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res 447 (1988), 346-352.
77. Klapstein, GJ, Fisher, RS, Zanjani, H, Cepeda, C, Jokel, ES, Chesselet, MF, Levine, MS, Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86 (2001), 2667-2677.
78. Kreitzer, AC, Malenka, RC, Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 (2007), 643-647.
79. Lei, W, Jiao, Y, Del Mar, N, Reiner, A, Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci 24 (2004), 8289-8299.
80. Levine, MS, Li, Z, Cepeda, C, Cromwell, HC, Altemus, KL, Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 24 (1996), 65-78.
81. Levine, MS, Cepeda, C, Hickey, MA, Fleming, SM, Chesselet, MF, Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27 (2004), 691-697.
82. Levine, MS, Klapstein, GJ, Koppel, A, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58 (1999), 515-532.
83. Li, JY, Plomann, M, Brundin, P, Huntington's disease: a synaptopathy?. Trends Mol Med 9 (2003), 414-420.
84. Lin, CH, Tallaksen-Greene, S, Chien, WM, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10 (2001), 137-144.
85. Lione, LA, Carter, RJ, Hunt, MJ, Bates, GP, Morton, AJ, Dunnett, SB, Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19 (1999), 10428-10437.
86. Lovinger, DM, Choi, S, Activation of adenosine A1 receptors initiates short-term synaptic depression in rat striatum. Neurosci Lett 199 (1995), 9-12.
87. Lovinger, DM, McCool, BA, Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73 (1995), 1076-1083.
88. Luthi-Carter, R, Strand, A, Peters, NL, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9 (2000), 1259-1271.
89. Maidment, NT, Lam, HA, Ackerson, LC, Rockenstein, E, Masliah, E, Dysregulation of dopamine transmission in mice overexpressing human wildtype alpha-synuclein. Abstract Viewer/Itinerary Planner. 2006, Society for Neuroscience Program No. 378.4, Atlanta, GA.
90. Mallet, N, Ballion, B, Le Moine, C, Gonon, F, Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci 26 (2006), 3875-3884.
91. Mangiarini, L, Sathasivam, K, Seller, M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996), 493-506.
92. Masliah, E, Rockenstein, E, Veinbergs, I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000), 1265-1269.
93. Menalled, L, Zanjani, H, MacKenzie, L, Koppel, A, Carpenter, E, Zeitlin, S, Chesselet, MF, Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol 162 (2000), 328-342.
94. Menalled, LB, Chesselet, MF, Mouse models of Huntington's disease. Trends Pharmacol Sci 23 (2002), 32-39.
95. Menalled, LB, Sison, JD, Dragatsis, I, Zeitlin, S, Chesselet, MF, Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465 (2003), 11-26.
96. Meredith, GE, Totterdell, S, Potashkin, JA, Surmeier, DJ, Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14:2 (2008), S112–S115.
97. Miller, BR, Walker, AG, Shah, AS, Barton, SJ, Rebec, GV, Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. J Neurophysiol 100 (2008), 2205-2216.
98. Milnerwood, AJ, Raymond, LA, Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 585 (2007), 817-831.
99. Milnerwood, AJ, Gladding, CM, Vasuta, OC, Graham, RK, Hayden, MR, Murphy, TH, Raymond, LA, Increased extrasynaptic NMDA receptor signalling in a transgenic mouse model of Huntington's disease. Abstract Viewer/Itinerary Planner. 2008, Society for Neuroscience Program No. 547.14, Washington, DC.
100. Milnerwood, AJ, Cummings, DM, Dallerac, GM, et al. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 15 (2006), 1690-1703.
101. Murphy, KP, Carter, RJ, Lione, LA, Mangiarini, L, Mahal, A, Bates, GP, Dunnett, SB, Morton, AJ, Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20 (2000), 5115-5123.
102. Neely, MD, Schmidt, DE, Deutch, AY, Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience 149 (2007), 457-464.
103. Nisenbaum, ES, Berger, TW, Grace, AA, Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons. J Neurophysiol 67 (1992), 477-481.
104. Palacino, JJ, Sagi, D, Goldberg, MS, Krauss, S, Motz, C, Wacker, M, Klose, J, Shen, J, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004), 18614-18622.
105. Paladini, CA, Robinson, S, Morikawa, H, Williams, JT, Palmiter, RD, Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci USA 100 (2003), 2866-2871.
106. Pallier, PN, Maywood, ES, Zheng, Z, et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci 27 (2007), 7869-7878.
107. Papadia, S, Hardingham, GE, The dichotomy of NMDA receptor signaling. Neuroscientist 13 (2007), 572-579.
108. Picconi, B, Passino, E, Sgobio, C, et al. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 22 (2006), 143-152.
109. Pisani, A, Bernardi, G, Ding, J, Surmeier, DJ, Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30 (2007), 545-553.
110. Polymeropoulos, MH, Lavedan, C, Leroy, E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045-2047.
111. Porritt, MJ, Batchelor, PE, Hughes, AJ, Kalnins, R, Donnan, GA, Howells, DW, New dopaminergic neurons in Parkinson's disease striatum. Lancet 356 (2000), 44-45.
112. Rasmussen, A, Macias, R, Yescas, P, Ochoa, A, Davila, G, Alonso, E, Huntington disease in children: genotype–phenotype correlation. Neuropediatrics 31 (2000), 190-194.
113. Rebec, GV, Conroy, SK, Barton, SJ, Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137 (2006), 327-336.
114. Reiner, A, Jiao, Y, Del Mar, N, Laverghetta, AV, Lei, WL, Differential morphology of pyramidal tract-type and intratelencephalically projecting-type corticostriatal neurons and their intrastriatal terminals in rats. J Comp Neurol 457 (2003), 420-440.
115. Rockenstein, E, Mallory, M, Hashimoto, M, Song, D, Shults, CW, Lang, I, Masliah, E, Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68 (2002), 568-578.
116. Schultz, W, Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms. Prog Neurobiol 18 (1982), 121-166.
117. Schultz, W, Ungerstedt, U, Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp Brain Res 33 (1978), 159-171.
118. Shelbourne, PF, Killeen, N, Hevner, RF, et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8 (1999), 763-774.
119. Shimura, H, Hattori, N, Kubo, S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000), 302-305.
120. Shuen, JA, Chen, M, Gloss, B, Calakos, N, Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 28 (2008), 2681-2685.
121. Slow, EJ, van Raamsdonk, J, Rogers, D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12 (2003), 1555-1567.
122. Smeal, RM, Keefe, KA, Wilcox, KS, Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum. Eur J Neurosci 28 (2008), 2041-2052.
123. Smeal, RM, Gaspar, RC, Keefe, KA, Wilcox, KS, A rat brain slice preparation for characterizing both thalamostriatal and corticostriatal afferents. J Neurosci Methods 159 (2007), 224-235.
124. Smith, R, Brundin, P, Li, JY, Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol Life Sci 62 (2005), 1901-1912.
125. Spampanato, J, Gu, X, Yang, XW, Mody, I, Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 157 (2008), 606-620.
126. Spillantini, MG, Schmidt, ML, Lee, VM, Trojanowski, JQ, Jakes, R, Goedert, M, Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839-840.
127. Stack, EC, Dedeoglu, A, Smith, KM, et al. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 27 (2007), 12908-12915.
128. Starling, AJ, Andre, VM, Cepeda, C, de Lima, M, Chandler, SH, Levine, MS, Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 82 (2005), 377-386.
129. Steiner, H, Gerfen, CR, Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 88 (1999), 795-810.
130. Strong, TV, Tagle, DA, Valdes, JM, et al. Widespread expression of the human and rat Huntington's disease gene in brain and non-neural tissues. Nat Genet 5 (1993), 259-265.
131. Taverna, S, Ilijic, E, Surmeier, DJ, Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci 28 (2008), 5504-5512.
132. Tepper, JM, Koos, T, Wilson, CJ, GABAergic microcircuits in the neostriatum. Trends Neurosci 27 (2004), 662-669.
133. Tepper, JM, Wilson, CJ, Koos, T, Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev 58 (2008), 272-281.
134. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993), 971-983.
135. Thompson, PD, Berardelli, A, Rothwell, JC, Day, BL, Dick, JP, Benecke, R, Marsden, CD, The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 111:Pt 2 (1988), 223-244.
136. Tseng, KY, Kasanetz, F, Kargieman, L, Riquelme, LA, Murer, MG, Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions. J Neurosci 21 (2001), 6430-6439.
137. Uhl, GR, Navia, B, Douglas, J, Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. J Neurosci 8 (1988), 4755-4764.
138. Ungerstedt, U, 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 (1968), 107-110.
139. Van Raamsdonk, JM, Pearson, J, Slow, EJ, Hossain, SM, Leavitt, BR, Hayden, MR, Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 25 (2005), 4169-4180.
140. Vincent, S, Hokfelt, T, Christensson, I, Terenius, L, Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol 85 (1982), 251-252.
141. von Horsten, S, Schmitt, I, Nguyen, HP, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 12 (2003), 617-624.
142. Vonsattel, JP, DiFiglia, M, Huntington disease. J Neuropathol Exp Neurol 57 (1998), 369-384.
143. Vonsattel, JP, Myers, RH, Stevens, TJ, Ferrante, RJ, Bird, ED, Richardson, EP Jr., Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44 (1985), 559-577.
144. Wang, H, Pickel, VM, Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus. J Comp Neurol 442 (2002), 392-404.
145. Wang, L, Fleming, SM, Chesselet, MF, Tache, Y, Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 19 (2008), 873-876.
146. Watson, JB, Hatami, A, David, H, Masliah, E, Roberts, K, Evans, CE, Levine, MS, Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 159 (2009), 501-513.
147. Wheeler, VC, White, JK, Gutekunst, CA, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9 (2000), 503-513.
148. White, JK, Auerbach, W, Duyao, MP, Vonsattel, JP, Gusella, JF, Joyner, AL, MacDonald, ME, Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17 (1997), 404-410.
149. Wilson, CJ, Basal ganglia. Shepherd, GW, (eds.) The Synaptic Organization of the Brain, 1990, Oxford University Press, Oxford, 279-316.
150. Wood, JD, MacMillan, JC, Harper, PS, Lowenstein, PR, Jones, AL, Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Hum Mol Genet 5 (1996), 481-487.
151. Woodman, B, Butler, R, Landles, C, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72 (2007), 83-97.
152. Wu, N, Cepeda, C, Masliah, E, Levine, MS, Abnormal glutamate and dopamine receptor function in the striatum of α-synuclein-overexpressing mice. Abstract Viewer/Itinerary Planner. 2005, Society for Neuroscience Program No. 85.12, Washington, DC.
153. Wu, N, Cepeda, C, Zhuang, X, Levine, MS, Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice. J Neurophysiol 98 (2007), 423-432.
154. Yan, Z, Hsieh-Wilson, L, Feng, J, Tomizawa, K, Allen, PB, Fienberg, AA, Nairn, AC, Greengard, P, Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 2 (1999), 13-17.
155. Yang, SH, Cheng, PH, Banta, H, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453 (2008), 921-924.
156. Yin, HH, Lovinger, DM, Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci USA 103 (2006), 8251-8256.
157. Zhou, QY, Palmiter, RD, Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83 (1995), 1197-1209.
158. Zhuang, X, Oosting, RS, Jones, SR, Gainetdinov, RR, Miller, GW, Caron, MG, Hen, R, Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98 (2001), 1982-1987.
159. Zuccato, C, Cattaneo, E, Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 81 (2007), 294-330.